<- Go Home
Celgene Corporation
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. The company offers ABRAXANE, a paclitaxel powder for injectable suspension nanoparticle; IDHIFA that are enasidenib tablets; INREBIC, which are fedratinib capsules; ISTODAX, a lyophilized powder for injection; ONUREG that are azacitidine tablets; POMALYST, pomalidomide capsules; REBLOZYL, an injection for luspatercept; REVLIMID that are lenalidomide capsules; THALOMID, which are thalidomide capsules; VIDAZA, an injection of azacytidine; and ZEPOSIA that are ozanimod capsules. It provides pharmaceuticals in the areas of oncology, hematology, immunoscience, cardiovascular disease, and fibrosis. The company was incorporated in 1986 and is based in Summit, New Jersey. Celgene Corporation operates as a subsidiary of Bristol-Myers Squibb Company.
Market Cap
$77.0B
Volume
7.0M
Cash and Equivalents
$9.6B
EBITDA
$8.9B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$15.6B
Profit Margin
92.04%
52 Week High
$110.70
52 Week Low
$58.59
Dividend
N/A
Price / Book Value
6.37
Price / Earnings
13.31
Price / Tangible Book Value
-6.26
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
$8.3B
Return on Equity
69.39%
Return on Assets
13.69
Cash and Short Term Investments
$10.9B
Debt
$20.1B
Equity
$12.1B
Revenue
$17.0B
Unlevered FCF
$6.2B
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium